Microba Life Sciences and Illumina partner to accelerate microbiome research

Leaders in precision gut microbiome science Microba Life Sciences has united with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies to advance understanding of the human gut microbiome in human health and disease.

The partnership will bring together Microba’s high-quality proprietary gut microbiome analysis platform with Illumina’s revolutionising Next Generation Sequencing tools to generate the accurate metagenomic data researchers require to make new discoveries.

Focusing activities in Asia Pacific and Japan, the duo will work together to enable research studies that reveal connections between the microbiome and human health from mental health and Parkinson’s disease to nutrition and sleep.

Such projects wouldn’t be possible without access to the accurate and high-resolution data that Illumina’s methodology enables, combined with Microba’s analysis.

Microba CEO Mr Blake Wills said the partnership would further accelerate the adoption of gut microbiome profiling for research into human disease.

“There remains huge potential for research to enhance our understanding of the role the gut microbiome plays in health and disease states,” he said.

“Combining Microba’s deep analysis capability with Illumina’s advanced technology, this potential is being realised.”

Illumina Vice President and General Manager of Asia Pacific and Japan, Ms Blake Wills explained that by working together the companies could rapidly deliver insights and the accessibility of gut microbiome analysis.

“With genomic sequencing at the forefront of understanding human health, the partnership will aim to explore and demonstrate potential applications of gut microbiome profiling by combining Illumina’s established credibility and global reach in NGS with Microba’s progressive analytical services,” she said.

With current projects including The University of Queensland exploring treatments for Parkinson’s disease and the value of faecal microbiome transplants (FMT) to treat depression with the Food and Mood Centre, it’s expected that the partnership will increase the uptake of high-quality microbiome research to enable new discoveries.